New Radspherin® data published
Oncoinvent is pleased to announce today that Oncoinvent researchers have published data demonstrating the efficacy of the Radspherin® in two separate models of peritoneal carcinomatosis originating from ovarian cancer cell lines in the journal Translational Oncology.
Summary of findings
In both models, intraperitoneal treatment with Radspherin® gave significant antitumor effect with either considerably reduced tumor volume or a survival benefit. An advantageous discovery was that only a few kilobecquerels were needed to yield therapeutic effects. The treatment was well tolerated up to a dose of 1000 kBq/kg with no signs of acute or subacute toxicity observed. Intraperitoneal α-therapy with Radspherin® demonstrated a significant potential for treatment of peritoneal micrometastases in ovarian carcinoma.
A free access copy of the article can be obtained through the science direct website: https://www.sciencedirect.com/science/article/pii/S1936523317304
For further information, please contact:
Jan A. Alfheim, Chief Executive Officer Cell: +47 46 44 00 45 Email: email@example.com
Ole Peter Nordby, Chief Financial Officer
Cell: +47 41 28 71 79
Radspherin® is a novel alpha-emitting radioactive microsphere designed for treatment of metastatic cancers in body cavities. The radium based therapeutic, Radspherin® has shown strong and consistent anticancer activity without any signs of product related toxicity in preclinical studies. It is anticipated that the product can potentially treat several forms of metastatic cancer. The first clinical indication for Radspherin® will be treatment of peritoneal carcinomatosis. Peritoneal carcinomatosis is one of the most serious complications of gastrointestinal and gynecological malignancies.
Oncoinvent AS is a privately held Norwegian company based in Oslo, Norway. The company is committed to developing new innovative products to provide better treatment options to cancer patients.
The company's founders started Oncoinvent in 2010 with a view to designing better cancer treatments by applying known physical and chemical principles of selected materials in new ways to maximize their medical benefit while minimizing potential safety concerns. This approach has allowed the company to develop a rich development pipeline and to explore multiple technological avenues before selecting a lead product candidate for preclinical testing.